|
Synonyms: BLV | formerly Myrcludex B | Hepcludex®
bulevirtide is an approved drug (EMA (2020), UK HMRA (2021))
Compound class:
Peptide or derivative
Comment: Bulevirtide is a lipopeptide antiviral agent. It blocks entry of the hepatitis-causing viruses HBV and HDV into hepatocytes [1]. The peptide structure of bulevirtide is derived from the pre-S1 domain of the large envelope protein of HBV surface antigen (HBsAg) [4], that binds to the heoatocyte expressed surface protein sodium/bile acid and sulphated solute cotransporter 1 (NTCP; SLC10A1) to mediate viral entry into host cells. Bulevirtide functionally blocks this entry process [3].
|
Classification  |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (EMA (2020), UK HMRA (2021)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10692 | bulevirtide |
| Synonyms |
| BLV | formerly Myrcludex B | Hepcludex® |
| Database Links |
|
| GtoPdb PubChem SID | 483123323 |
| Search PubMed clinical trials | bulevirtide |
| Search PubMed titles | bulevirtide |
| Search PubMed titles/abstracts | bulevirtide |
